Is Whitehawk Therapeutics, Inc. (WHWK) overvalued? · $202.8M cap
Whitehawk Therapeutics, Inc. (WHWK) is a biotechnology company listed on NASDAQ.
This page asks whether Whitehawk Therapeutics, Inc. (WHWK) looks expensive on cached numbers — not a short thesis.
Latest reported WHWK revenue for 2026-06-30 was $0. Net income was -$38.8M. WHWK currently screens at market cap $202.8M.
WHWK currently screens at market cap $202.8M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next WHWK 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the WHWK stock page for the full model, not this heading.
Not investment advice.